BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33916879)

  • 1. Modeling Rett Syndrome with Human Pluripotent Stem Cells: Mechanistic Outcomes and Future Clinical Perspectives.
    Gomes AR; Fernandes TG; Cabral JMS; Diogo MM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells.
    Andoh-Noda T; Inouye MO; Miyake K; Kubota T; Okano H; Akamatsu W
    CNS Neurol Disord Drug Targets; 2016; 15(5):544-50. PubMed ID: 27071793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.
    Cheung AY; Horvath LM; Grafodatskaya D; Pasceri P; Weksberg R; Hotta A; Carrel L; Ellis J
    Hum Mol Genet; 2011 Jun; 20(11):2103-15. PubMed ID: 21372149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2).
    Tanaka Y; Kim KY; Zhong M; Pan X; Weissman SM; Park IH
    Hum Mol Genet; 2014 Feb; 23(4):1045-55. PubMed ID: 24129406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2.
    Chen X; Han X; Blanchi B; Guan W; Ge W; Yu YC; Sun YE
    Protein Cell; 2021 Aug; 12(8):639-652. PubMed ID: 32851591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Rett syndrome using pluripotent stem cells.
    Dajani R; Koo SE; Sullivan GJ; Park IH
    J Cell Biochem; 2013 Nov; 114(11):2446-53. PubMed ID: 23744605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease.
    Pejhan S; Rastegar M
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33429932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage.
    Andoh-Noda T; Akamatsu W; Miyake K; Matsumoto T; Yamaguchi R; Sanosaka T; Okada Y; Kobayashi T; Ohyama M; Nakashima K; Kurosawa H; Kubota T; Okano H
    Mol Brain; 2015 May; 8():31. PubMed ID: 26012557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome.
    Kim KY; Hysolli E; Park IH
    Proc Natl Acad Sci U S A; 2011 Aug; 108(34):14169-74. PubMed ID: 21807996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
    Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
    Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model.
    Ananiev G; Williams EC; Li H; Chang Q
    PLoS One; 2011; 6(9):e25255. PubMed ID: 21966470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors.
    Varderidou-Minasian S; Hinz L; Hagemans D; Posthuma D; Altelaar M; Heine VM
    Mol Autism; 2020 May; 11(1):38. PubMed ID: 32460858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons.
    Xiang Y; Tanaka Y; Patterson B; Hwang SM; Hysolli E; Cakir B; Kim KY; Wang W; Kang YJ; Clement EM; Zhong M; Lee SH; Cho YS; Patra P; Sullivan GJ; Weissman SM; Park IH
    Mol Cell; 2020 Jul; 79(1):84-98.e9. PubMed ID: 32526163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
    Gadalla KK; Bailey ME; Cobb SR
    Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling.
    Mellios N; Feldman DA; Sheridan SD; Ip JPK; Kwok S; Amoah SK; Rosen B; Rodriguez BA; Crawford B; Swaminathan R; Chou S; Li Y; Ziats M; Ernst C; Jaenisch R; Haggarty SJ; Sur M
    Mol Psychiatry; 2018 Apr; 23(4):1051-1065. PubMed ID: 28439102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of Rett syndrome and MECP2 disorders to autism.
    Neul JL
    Dialogues Clin Neurosci; 2012 Sep; 14(3):253-62. PubMed ID: 23226951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the pathogenesis of Rett syndrome using cell models.
    Lu S; Chen Y; Wang Z
    Animal Model Exp Med; 2022 Dec; 5(6):532-541. PubMed ID: 35785421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rett syndrome and MeCP2.
    Liyanage VR; Rastegar M
    Neuromolecular Med; 2014 Jun; 16(2):231-64. PubMed ID: 24615633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential brain region-specific expression of MeCP2 and BDNF in Rett Syndrome patients: a distinct grey-white matter variation.
    Pejhan S; Siu VM; Ang LC; Del Bigio MR; Rastegar M
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):735-750. PubMed ID: 32246495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution.
    Kaufmann WE; Johnston MV; Blue ME
    Brain Dev; 2005 Nov; 27 Suppl 1():S77-S87. PubMed ID: 16182491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.